This page is linked to:
=====================================
Critiquing: Dr. Michael A. Friedman, Dr. Mark G. Malkin, Dr. Mario Sznol, Robert B. Lanman, Memorial Sloan-Kettering Cancer Center, Mayo Clinic, Department of Health & Human Services (HHS), Public Health Service, Quality Assurance and Compliance Section, Regulatory Affairs Branch (RAB), Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Center (NCI) at the National Institutes of Health (NIH), Stanislaw Burzynski: On the arrogance of ignorance about cancer and targeted therapies
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/08/critiquing-stanislaw-burzynski-on-the-arrogance-of-ignorance-about-cancer-and-targeted-therapies/
======================================
[4] – 1991 (10/31/1991) – Dr. Michael A. Friedman Memorandum to Dr. Bruce A. Chabner (1 pg.)
——————————————————————
Michael A. Friedman, M.D., Associate Director, Cancer Therapy Evaluation Program (CTEP), Department of Health &Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI)
Memorandum
(Unconventional Therapy File. – written in)
Subject: Antineoplastons
To: Bruce A. Chabner, M.D.
Director, Division of Cancer Treatment
I thought you would be interested in this for several reasons:
1. Our Unconventional Cancer Treatment approach seems to be working well (thanks to Mike Hawkins).
2. Our on-site review process is working well (thanks to Dorothy Macfarlane)
3. Antineoplastons deserve a closer look
It turns out that the agents are well defined, pure chemical entities
They are relatives of Thalidomide with presumed good CNS penetration
We are working with DTEP on them
The human brain tumor responses are real
We will keep you informed
(Mike Why not test These in a phase II trial – written in)
